Press Release

CYTOCHROMA COMPLETES ENROLLMENT IN PHASE II PSORIASIS

TRIAL

______________________________________________________________________

Markham, Ontario, Canada — March 6, 2007 — Cytochroma Inc. announced today

that it has completed the enrollment of patients in a Phase II clinical trial of CTA018

Cream for chronic plaque psoriasis.

The ongoing Phase II trial is a randomized, double-blind, placebo-controlled study being

conducted in 16 dermatology clinics located throughout the continental United States. A

total of 147 subjects with chronic plaque psoriasis have been enrolled and are undergoing

a 12-week course of treatment with one of three different concentrations of CTA018

Cream or a matching placebo. All subjects are receiving once daily topical treatment

over a maximum of 15% body surface area. The primary efficacy endpoint of the trial is

the Physician Static Global Assessment, which is a commonly used psoriasis severity

assessment scale required by the United States Food and Drug Administration. The

primary safety endpoints of the trial include adverse events and clinical laboratory

measurements. Patient perceptions of CTA018 Cream are being evaluated in addition to

several other secondary endpoints.

“We are pleased that enrollment has been completed ahead of schedule by Mayo Clinical

Trial Services of Rochester, MN,” said Jukka Karjalainen, M.D., Ph.D., Executive

Director, Product Development (Dermatology) at Cytochroma. “Based on the results

obtained in two earlier clinical trials, we anticipate that CTA018 Cream, with its novel

dual mechanism of action, will show a clear benefit over current treatment options when

the results of this trial are released in July 2007.”

“Many chronic plaque psoriasis patients are not satisfied with the efficacy of current

topical treatments, and even products that are effective are often discontinued over time

due to side effects or treatment resistance,” said Dr. Mark Lebwohl, Chairman of the

Medical Board of the National Psoriasis Foundation and Professor and Chairman,

Department of Dermatology, The Mount Sinai Medical Center, New York. “Topical

treatments with greater efficacy and tolerability are needed to address this patient

population, which represents the majority of the nearly 7 million psoriasis patients in the

United States.”

About CTA018

CTA018 is a novel vitamin D analog with a dual mechanism of action designed to be

both a strong activator of the vitamin D signaling pathway and a potent inhibitor of

CYP24 activity (the enzyme responsible for the catabolism of vitamin D). This

compound was specifically designed by Professor Gary H. Posner, Ph.D. and is protected

under patents and patent applications exclusively licensed to Cytochroma Inc. from the

Johns Hopkins University. CTA018 Cream was previously studied in two Phase I

clinical trials and demonstrated to be both well tolerated and efficacious in the treatment

of patients with psoriasis.

About Psoriasis

Psoriasis is a common immune-mediated chronic skin disease often characterized by red,

scaly plaques that itch, burn, sting, and bleed easily. It afflicts approximately 125 million

people worldwide; more than 70% of patients have the mild to moderate form. Psoriasis

is found in all age groups and often seriously compromises the quality of life of those

affected. Current methods of treatment are either inconvenient, show poor remission

rates, and/or have serious side effects. Cytochroma has recognized that there is a need

for improved therapies.

About Cytochroma Inc.

Cytochroma (www.cytochroma.com) is an integrated specialty pharmaceutical company

engaged in the development and commercialization of proprietary products to treat and

prevent the clinical consequences of diseases and disorders related to vitamin D hormone

deficiency. The company has an advanced portfolio of new products targeting vitamin D

deficiency and secondary hyperparathyroidism in patients with moderate to severe

chronic kidney disease and end-stage renal disease. In addition, the company is

developing novel vitamin D therapies to treat hyperproliferative disorders such as cancer

and psoriasis.

For Information Contact:

Eric J. Messner

Vice President, Commercial Operations

905-479-5306 ext. 338

eric.messner@cytochroma.com